Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Recruiting 3Active not recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Glioblastoma 52Brain Neoplasms 28Glioma 22Gliosarcoma 19Melanoma 18Astrocytoma 17Central Nervous System Neoplasms 11Oligodendroglioma 10Neoplasms 9Neoplasm Metastasis 8Recurrence 6Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Lymphoma 4Ependymoma 4Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Sarcoma, Ewing 2Neurologic Manifestations 2Neuroectodermal Tumors, Primitive 2Neoplasms, Second Primary 2Meningeal Carcinomatosis 2Medulloblastoma 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Tetanus 1Spinal Cord Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Recurrent 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Magnetic Resonance Spectroscopy 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1fosbretabulin 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1Serotonin 1Quality of Life 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroendocrine Tumors × Temozolomide × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡